Authors’ Disclosures
Melanoma, cancers, Tumor, P., Lyell
MELANOMA, DISORDERS, CANCERS, TUMOR, LYELL
P. Munster reports grants from Amgen, Pfizer, AstraZeneca, GSK, Novartis, Oric, Revolution Medicine, Aevinas, Cyteir, Tempest, Arch, and H3Bio during the conduct of the study; personal fees and other from Alessa and Janssen, Atlas, RasCal; non-financial support from Hap10; personal fees from Parthenon outside the submitted work. L.C. Villaruz reports personal fees from Takeda, Sanofi, Jannsen, InterVenn Biosciences, Daichi Sankyo, Jazz, and BMS outside the submitted work. G.T. Gibney reports other from Incyte during the conduct of the study; personal fees from Merck, Bristol Myers Squibb, Novartis, Huyabio, Incyte, Immunocore, Lyell, Iovance, Eisai, Regeneron, Sapience Therapeutics, Genentech, and Exicure; other from Exelixis outside the submitted work. F.S. Hodi reports personal fees and other from Incyte during the conduct of the study; grants from Bristol Myers Squibb; grants and personal fees from Novartis; personal fees from Merck, Aduro, Amgen, 7 hills Pharma, Apricity, Bicara, Bioentre, Catalym, Checkpoint Therapeutics, Compass Therapeutics, Genentech, Gossamer, Immunocore, Iovance, Merck, Pieris Pharmaceutical, Surface, Trillium, AstraZeneca, Corner Therapeutics, and Zumutor outside the submitted work; in addition, F.S. Hodi has a patent to Methods for Treating MICA-Related Disorders (#20100111973) pending and with royalties paid, a patent to Tumor antigens and uses thereof (#7250291) issued, a patent to Angiopoiten-2 Biomarkers Predictive of Anti-immune checkpoint response (#20170248603) pending, a patent to Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms (#20160340407) pending, a patent to Therapeutic peptides (#20160046716) pending, a patent to METHODS OF USING PEMBROLIZUMAB AND TREBANANIB pending, a patent to Vaccine compositions and methods for restoring NKG2D pathway function against cancers Patent number: 10279021 issued and with royalties paid, a patent to Antibodies that bind to MHC class I polypeptide-related sequence A Patent number: 10106611 issued and with royalties paid, and a patent to ANTI-GALECTIN ANTIBODY BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT AND ANTI-ANGIOGENESIS RESPONSES Publication number: 20170343552 pending. N.B. Mettu reports other from Mereo Biopharma, Erytech Pharma, Repare Therapeutics, Syros Pharmaceuticals, Merck Sharpe & Dohme, AstraZeneca, LP, Incyte, Compass Therapeutics, Biomed Valley Discoveries, Aravive, Inc., Nucana, and Genentech; grants from Leap Therapeutics outside the submitted work. M. Jones reports other from Incyte during the conduct of the study. M. Smith reports non-financial support from Envision Pharma Group during the conduct of the study; and employment and stock ownership with Incyte Corporation. No disclosures were reported by the other authors.